The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 110-115

  Ghanizadeh, Ahmad ^a   Nikseresht, Mohammad Saeed ^a   Sahraian, Ali ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Body mass index; Clinical trial; Schizophrenia; Weight; Zonisamide

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; FLUOXETINE; LITHIUM; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE; AGED; ANOREXIA; ARTICLE; BLURRED VISION; BODY MASS; BODY WEIGHT; BRONCHITIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EDUCATIONAL STATUS; FATIGUE; FEMALE; GENDER; HEMATURIA; HUMAN; INCREASED APPETITE; MALE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MUSCLE TWITCH; NERVOUSNESS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; URINE RETENTION; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; OBESITY; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN; YOUNG ADULT;

EID: 84877101040     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.021     Document Type: Article

References (33)

1. APA Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
2. Araujo J.R., Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr. Neuropharmacol. 2012, 10(1):49-52.
3. Ball M.P., Warren K.R., Feldman S., McMahon R.P., Kelly D.L., Buchanan R.W. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin. Schizophr. Relat. Psychoses 2011, 5(1):17-25.
4. Baptista T., Uzcategui E., Rangel N., El Fakih Y., Galeazzi T., Beaulieu S., de Baptista E.A. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 2008, 159(1-2):250-253.
5. Bell R.C., Farmer S., Ries R., Srebnik D. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr. Serv. 2009, 60(12):1686-1689.
6. Brodie M.J., Ben-Menachem E., Chouette I., Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol. Scand. Suppl. 2012, (194):19-28.
7. Bustillo J.R., Lauriello J., Parker K., Hammond R., Rowland L., Bogenschutz M., Keith S. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003, 28(3):527-529.
8. Cho S.J., Yook K., Kim B., Choi T.K., Lee K.S., Kim Y.W., Lee J.E., Suh S., Yook K.H., Lee S.H. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(1):208-211.
9. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 2004, 49(11):753-760.
10. Dauphinais D., Knable M., Rosenthal J., Polanski M., Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol. Bull. 2011, 44(1):5-17.
11. Gadde K.M., Franciscy D.M., Wagner H.R., Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289(14):1820-1825.
12. Hoffmann V.P., Case M., Jacobson J.G. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J. Clin. Psychiatry 2012, 73(2):216-223.
13. Kay S.R., Flszbein A., Opfer L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261.
14. Kelly D.L., Gorelick D.A., Conley R.R., Boggs D.L., Linthicum J., Liu F., Feldman S., Ball M.P., Wehring H.J., McMahon R.P., Huestis M.A., Heishman S.J., Warren K.R., Buchanan R.W. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J. Clin. Psychopharmacol. 2011, 31(1):86-91.
15. Kim C.S. Zonisamide effective for weight loss in women. J. Fam. Pract. 2003, 52(8):600-601.
16. Ko Y.H., Joe S.H., Jung I.K., Kim S.H. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol. 2005, 28(4):169-175.
17. Matson K.L., Fallon R.M. Treatment of obesity in children and adolescents. J. Pediatr. Pharmacol. Ther. 2012, 17(1):45-57.
18. McElroy S.L., Winstanley E., Mori N., Martens B., McCoy J., Moeller D., Guerdjikova A.I., Keck P.E. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J. Clin. Psychopharmacol. 2012, 32(2):165-172.
19. Murata M. Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc.) 2010, 46(4):251-258.
20. Narula P.K., Rehan H.S., Unni K.E., Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr. Res. 2010, 118(1-3):218-223.
21. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995, 22(3):193-205.
22. Okada M., Hirano T., Kawata Y., Murakami T., Wada K., Mizuno K., Kondo T., Kaneko S. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999, 34(2-3):187-197.
23. Papanastasiou E. Interventions for the metabolic syndrome in schizophrenia: a review. Ther. Adv. Endocrinol. Metab. 2012, 3(5):141-162.
24. Poyurovsky M., Pashinian A., Gil-Ad I., Maayan R., Schneidman M., Fuchs C., Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am. J. Psychiatry 2002, 159(6):1058-1060.
25. Poyurovsky M., Tal V., Maayan R., Gil-Ad I., Fuchs C., Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur. Neuropsychopharmacol. 2004, 14(4):332-336.
26. Said M.A., Sulaiman A.H., Habil M.H., Das S., Bakar A.K., Yusoff R.M., Loo T.H., Bakar S.A. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med. J. 2012, 53(12):801-807.
27. Takayanagi Y., Cascella N.G., Sawa A., Eaton W.W. Diabetes is associated with lower global cognitive function in schizophrenia. Schizophr. Res. 2012, 142(1-3):183-187.
28. Terry P., Gilbert D.B., Cooper S.J. Dopamine receptor subtype agonists and feeding behavior. Obes. Res. 1995, 3(Suppl. 4):515S-523S.
29. Wallingford N.M., Sinnayah P., Bymaster F.P., Gadde K.M., Krishnan R.K., McKinney A.A., Landbloom R.P., Tollefson G.D., Cowley M.A. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008, 33(12):2922-2933.
30. Wang M., Tong J.H., Zhu G., Liang G.M., Yan H.F., Wang X.Z. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr. Res. 2012, 138(1):54-57.
31. Wu R.R., Jin H., Gao K., Twamley E.W., Ou J.J., Shao P., Wang J., Guo X.F., Davis J.M., Chan P.K., Zhao J.P. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 2012, 169(8):813-821.
32. Yang J., Lee M.S., Joe S.H., Jung I.K., Kim S.H. Zonisamide-induced weight loss in schizophrenia: case series. Clin. Neuropharmacol. 2010, 33(2):104-106.
33. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108(8):1167-1174.